Amneal Pharmaceuticals AMRX · NASDAQ
$19.36 +0.94% (+$0.18)
Summary
48 / 100 · Bulios Score
What speaks for it
- It earns 14 USD a year on every 100 USD of invested capital.
- Revenue grew by 11% a year over the last 3 years.
What to watch
- The share price is above the Bulios Fair Price.
- Repaying its net debt would take 4.1 years of operating profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 39.3 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 8.7% a year over 5 years. Over the last 3 years it grew by 11% a year.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 61 USD
- Research and development 5.7 USD
- Sales and administration 21 USD
- Taxes and other 7.9 USD
- Net profit 5.0 USD
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10 USD
Out of every 100 USD of revenue, 5.0 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 33.6 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 11
- Hold 6
- Sell 0
Today's price within the analysts' price targets
The average target of $23.2 is 20% above today's price. 65% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Specialty Segment 100%
By region
- Specialty Segment 100%
Specialty Segment brings in 100% of revenue.
Segments in detail